Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04163952 | Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin | terminated | Phase 1 | 5 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04862455 | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer | terminated | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 23, 2026 |
| clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05987176 | Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases(NELMAS) | terminated | Phase 2 | 1 | Imperial College LondonOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04770272 | Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy(neoMono) | terminated | Phase 2 | 442 | Palleos Healthcare GmbHINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT02917759 | Liver and Biliary Tumor Tissue Registry | terminated | — | 1,000 | Mayo ClinicOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | terminated | Phase 2 | 19 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01048853 | Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer | terminated | N/A | 137 | M.D. Anderson Cancer CenterOTHER | 8 | Jan 7, 2026 | clinicaltrials |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | terminated | Phase 1 | 78 | Fusion Pharmaceuticals Inc.INDUSTRY | 3 | Jan 7, 2026 | clinicaltrials |
| NCT04578106 | Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy(ELPIS) | terminated | Phase 2 | 5 | Fundacio Clinic BarcelonaOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM)(OPPIDOM) | terminated | N/A | 8 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT04805788 | Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer | terminated | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer | terminated | Phase 1 | 1 | Baptist Health South FloridaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04986852 | Olinvacimab With Pembrolizumab in Patients With mTNBC | terminated | Phase 2 | 19 | PharmAbcineINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 24, 2025 | clinicaltrials |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer(SURGIGAST) | terminated | Phase 3 | 6 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03225547 | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | terminated | Phase 2 | 24 | University of ChicagoOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04831138 | Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma | terminated | N/A | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05044676 | Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma(IMMUNOCELL) | terminated | — | 4 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05171166 | Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | terminated | Phase 2 / Phase 3 | 18 | Peking UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.(HN1901) | terminated | Phase 2 | 17 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 227 | Mythic TherapeuticsINDUSTRY | 7 | Dec 16, 2025 | clinicaltrials |
| NCT06347809 | DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine | terminated | — | 24 | Mayo ClinicOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06818305 | Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT(EmFin-Nx) | terminated | Phase 2 | 10 | Jinling Hospital, ChinaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05289830 | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer | terminated | Phase 2 | 4 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT05583110 | Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer(TrasTUCAN) | terminated | Phase 2 | 13 | Spanish Breast Cancer Research GroupOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | terminated | Phase 1 | 6 | University of WashingtonOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04106531 | Validation of a Quality of Life Metric "Prolac-10"(Prolac-10) | terminated | — | 8 | Ohio State UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab(NIRADO) | terminated | Phase 2 | 51 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. | terminated | Phase 1 | 22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01946100 | Treatment of Multifocal Lung Adenocarcinoma | terminated | N/A | 100 | Mayo ClinicOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05954143 | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 11 | Bolt Biotherapeutics, Inc.INDUSTRY | 2 | Nov 20, 2025 | clinicaltrials |
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery | terminated | Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma(ELEVATE HNSCC) | terminated | Phase 2 | 193 | Gilead SciencesINDUSTRY | 11 | Nov 19, 2025 | clinicaltrials |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | terminated | Phase 1 | 4 | Colin D. Weekes, M.D., PhDOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | terminated | Phase 2 | 166 | SOTIO Biotech AGINDUSTRY | 9 | Nov 17, 2025 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | terminated | Phase 1 | 17 | Bolt Biotherapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | terminated | Phase 1 | 154 | Novartis PharmaceuticalsINDUSTRY | 9 | Nov 14, 2025 | clinicaltrials |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer | terminated | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 120 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) | terminated | Phase 2 | 18 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | terminated | Phase 2 | 102 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2026source: clinicaltrials